NASDAQ:IPA - ImmunoPrecise Antibodies Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$13.44
▲ +0.06 (0.45%)
1 month | 3 months | 12 months
Get New ImmunoPrecise Antibodies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for ImmunoPrecise Antibodies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $13.44.
Hold
The current consensus among 1 investment analysts is to hold stock in ImmunoPrecise Antibodies.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2021Industrial Alliance SecuritiesDowngradeBuy ➝ HoldLow
i
(Data available from 3/1/2016 forward)
ImmunoPrecise Antibodies logo
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Read More

Today's Range

Now: $13.44
$12.73
$13.85

50 Day Range

MA: N/A

52 Week Range

Now: $13.44
$2.09
$33.34

Volume

64,900 shs

Average Volume

133,332 shs

Market Capitalization

$225.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmunoPrecise Antibodies?

The following Wall Street sell-side analysts have issued research reports on ImmunoPrecise Antibodies in the last twelve months: Industrial Alliance Securities.
View the latest analyst ratings for IPA.

What is the current price target for ImmunoPrecise Antibodies?

0 Wall Street analysts have set twelve-month price targets for ImmunoPrecise Antibodies in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ImmunoPrecise Antibodies in the next year.
View the latest price targets for IPA.

What is the current consensus analyst rating for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IPA, but not buy more shares or sell existing shares.
View the latest ratings for IPA.

What other companies compete with ImmunoPrecise Antibodies?

How do I contact ImmunoPrecise Antibodies' investor relations team?

The company's listed phone number is 701 353 0022. The official website for ImmunoPrecise Antibodies is www.immunoprecise.com.